Smith, Meredith Y.
Janssens, Rosanne
Jimenez-Moreno, A. Cecilia
Cleemput, Irina
Muller, Mireille
Oliveri, Serena
Simons, Gwenda
Strammiello, Valentina
Huys, Isabelle
Falahee, Marie
Article History
Received: 27 November 2022
Accepted: 31 March 2023
First Online: 7 April 2023
Declarations
:
: The PREFER case studies, upon which our analysis was based, each underwent review and approval by medical ethics review committees in the countries where the studies were conducted. These included the following: Belgium—Medical Ethics Committee of University Hospital (UZ) KU Leuven/Research (S59790), France—Commission Nationale de l’Informatique et des Libertés (CNIL) (2036344), Germany—Ethik-Kommission der Friedrich-Alexander Universität (92_17 B), Italy—Comitato Etico Instituto Europeo di Oncologia (IEO) (R587/17-IEO 609), The Netherlands—Medisch Ethische Toetsings Commissie Erasmus Medical Centre (WT/ss/METC306661), Romania—Comisia de Bioetica a Medicamentului si a Dispozitivelor Medicale (CNBMDM) (5 SNI), Sweden—Regionala Etikprövningsnämnden Uppsala (EPN) (2017/001/1), United Kingdom -Newcastle University Ethics Committee (11307/2016). The patients/participants provided their written informed consent to participate in each of the PREFER case studies.
: Not applicable.
: MYS was a fulltime employee of AstraZeneca plc and a shareholder in the company at the time that this study was conducted. MYS is currently a fulltime employee of Evidera, Inc., PPD, a part of Thermo Fisher Scientific. MM is a fulltime employee of Novartis and a shareholder in the company. All other co-authors (IC, MF, IH, RJ, SO, GS, and VS) have no conflicts of interest to report. This article and its contents reflect the authors’ personal views and not the view of PREFER, IMI, the European Union or EFPIA, or any organization with which any of the authors are affiliated.